Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Summary

This clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surgery. In ER positive/HER2 negative breast cancers, after endocrine therapy and ablative radiotherapy, when image-guided biopsy shows no residual cancer, patients then receive standard endocrine therapy with no surgery. For patients who have HER2 positive and triple negative breast cancers and standard surgery, after systemic therapy, breast radiotherapy is being eliminated when the pathology from surgery shows no residual cancer.

Description

Eligibility

Age range

30+ years

Sex

Female

Healthy volunteers

No

Interventions

• Radiation
  Undergo EBRT

  Undergo EBRT

• Other
  Laboratory Biomarker Analysis

  Correlative studies

• Other
  Quality-of-Life Assessment

  Ancillary studies

• Other
  Questionnaire Administration

  Ancillary studies

• Radiation
  Partial Breast Irradiation

  Undergo partial breast irradiation

Locations (8)